LL-37 is the only known human cathelicidin — a 37-amino acid cationic antimicrobial peptide that serves as one of the most important first-line defense molecules in human innate immunity. Unlike conventional antibiotics that target specific bacterial pathways, LL-37 works through a fundamentally different mechanism: it physically disrupts the lipid membranes of pathogens, making resistance development significantly more difficult. It also disrupts bacterial biofilms — the protective matrix that shields antibiotic-resistant bacterial communities.

Human Cathelicidin: The Innate Defense Peptide

Cathelicidins are a family of antimicrobial peptides produced as part of the innate immune response. While many mammals have multiple cathelicidins, humans express only one: hCAP-18, which is proteolytically cleaved to release the active LL-37 C-terminal peptide. LL-37 is produced by neutrophils, macrophages, mast cells, NK cells, epithelial cells of the skin, gut, respiratory tract, and genital mucosa.

LL-37 is among the most rapidly mobilized antimicrobial defenses — it is stored in granules ready for immediate release upon detection of pathogen-associated molecular patterns. Its expression is also induced by vitamin D, making vitamin D deficiency a factor in reduced LL-37 expression and increased infection susceptibility.

Antimicrobial Mechanism: Membrane Disruption

LL-37's antimicrobial activity works through electrostatic attraction and membrane insertion: 1. The peptide's cationic charges (positive) are attracted to the anionic (negative) surface of bacterial and fungal membranes 2. LL-37 inserts into the lipid bilayer and adopts an amphipathic helical structure 3. This helical insertion disrupts membrane integrity — creating pores or detergent-like solubilization of the membrane 4. Bacterial and fungal cell contents leak out, causing rapid death

This membrane-disruptive mechanism is effective against: - Gram-positive bacteria (Staphylococcus aureus, including MRSA) - Gram-negative bacteria (E. coli, Pseudomonas aeruginosa) - Fungal pathogens (Candida species) - Enveloped viruses (HIV, influenza, herpes)

Biofilm Disruption: The Critical Advantage

Biofilms are communities of bacteria encased in a self-produced extracellular polysaccharide matrix that dramatically reduces antibiotic penetration. Chronic wound infections, implant-associated infections, and many recurrent bacterial infections involve biofilms that resist conventional antibiotics at 100–1000× normal concentrations.

LL-37 disrupts biofilm architecture through: - Inhibition of initial biofilm formation (binding to bacterial surfaces and preventing adherence) - Penetration through the extracellular matrix — enabled by LL-37's amphipathic structure and positive charge - Direct bacterial killing within the biofilm - Reduction of quorum sensing signals that coordinate biofilm behavior

This anti-biofilm activity is increasingly recognized as one of LL-37's most clinically important properties.

Immune Modulation Beyond Killing

LL-37 does more than kill pathogens — it is a central immune modulatory signal: - Promotes chemotaxis of monocytes, neutrophils, and T-cells to sites of infection - Activates dendritic cells, enhancing adaptive immune response initiation - Promotes angiogenesis for wound vascularization - Stimulates keratinocyte migration and proliferation for wound re-epithelialization - Modulates inflammatory cytokine production in context-dependent ways (pro-inflammatory in early infection; anti-inflammatory in resolution phase)